5/0 PATENT ABSTRACTS

The subject invention pertains to the use of modified PF4 and recombinant PF4(rPF4) as well as modified analogs (mutants) of PF4, and peptide fragments thereof, to inhibit angiogenesis. The modified PF4, analogs, and certain fragments are shown to have utility for treating angiogenic diseases and for the inhibi- tion of endothelial cell proliferation. Also, the subject invention concerns modification of PF4 which facilitate the targeting of the biological ac- tivity of PF4 to specific locations.

5112950

F A C T O R V I I I A N A L O G , P R E P A R A T I O N P R O C E S S , A N D

P H A R M A C E U T I C A L C O M P O S I T I O N C O N T A I N I N G I T

Pierre Meulien, Andrea Pavirani, Strasbourg, France assigned to Transgene S A

Factor VIII analog which has undergone dele- tion of amino acids 771 to 1666, prepared from eukaryotic cells transformed by an expression vector carrying the eDNA of the factor VIII which has undergone deletion.

5112948

M E T H O D S A N D C O M P O S I T I O N S F O R I N D U C I N G M O N O C Y T E

C Y T O T O X I C I T Y

C Michael Jones

The present disclosure relates to a new lyrnpho- kine molecule, referred to as Monocyte Cyto- toxicity Inducing Factor (MCF), and its use as in cancer and other types of therapy. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF and thereby provide a ready source for MCF isola- tion and purification. Sezary'Syndrome is a leukemic proliferation of OKT4 + lymphocytes. Sezary cells were isolated by differential cen- trifugation and fused to CEM.8azarC, an HGPRTase lacking clone of CEM. The hybrid cells were studied for their ability to produce soluble mediators of human monocyte cyto- toxicity. The product of a single clone, FtF3, which bore the surface phenotype of Sezary cells, was characterized. Monocyte cytotoxicity in- ducing factor was found to be stable at pH 2 for one hour, unlike interferon-gamma, and was found to be more heat stable as well. Moreover, treatment of MCF with antisera to interferons gamma, alpha, or a combination of gamma and alpha failed to neutralize its biologic activity. MCF binds to Matrex Gel Red A. MCF eluted from this dye-ligand was found to have an ap- parent molecular weight of I 1,500 Daltons by gel filtration and 14,700 Daltons by SDS- polyacrylamide gel electrophoresis. (SDS- PAGE). A molecular weight of 29,000 daltons was found by use of SDS-PAGE in a second species of MCF produced under serum-free con- ditions.

5112951

S E P A R A T I O N O F A N T I - M E T A L C H E L A T E A N T I B O D I E S

Daniel E Beidler, Rodney Jue assigned to Hybritech Incorporated

The present invention provides a method for the separation of anti-metal chelate antibodies from non-specific proteins, including antibodies, by applying a preparation containing the anti-metal chelate antibodies to an oxo acid derivatized solid support and eluting first with an elution buffer containing sufficient salt concentration to etute non-specific proteins but not sufficient to elute the anti-metal chelate antibodies and then increasing the salt concentration of the elution solution so as to elute the anti-metal chelate anti- bodies. In one embodiment, the oxo acid derivatized solid support is a sulfopropyl resin. Appropriate salts include sodium phosphate, sodium chloride and sodium acetate. The method can be used to separate monoclonal or polyclonal anti-metal chelate antibodies from non-specific proteins as well as to separate bi- functional anti-metal chelate antibodies from monoclonal anti-metal chelate antibodies and other non-specific proteins. The method is also useful for separating anti-metal chelate antibody fragments bearing antigen reactive regions from non-specific proteins.